Real-World data may reveal best Second-Line options after immunotherapy fails in lung cancer
NCT ID NCT07596524
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will look back at medical records of 300 people with advanced non-small cell lung cancer (NSCLC) whose disease got worse after first-line immunotherapy. Researchers want to see which second-line treatments were used and how well they worked in real-world practice. The goal is to help doctors choose better treatments for patients after immunotherapy stops working.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could provide clearer guidance on which second-line treatments work best for advanced lung cancer patients after immunotherapy fails.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient selection and real-world variability.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospirtal, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cancer Hospirtal, Chinese Academy of Medical Sciences, Shenzhen
Shenzhen, Guangdong, 518116, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, 030013, China
Contact Phone: •••-•••-•••• Email: •••••@•••••